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Abstract
Background: The purpose of this study was to evaluate neck control outcomes after definitive radiochemotherapy
without planned neck dissection in node-positive head and neck cancer.
Methods: We retrospectively reviewed medical records of fifty patients with node-positive head and neck cancer
who received definitive radiochemotherapy. Twelve patients subsequently underwent neck dissection for
suspicious recurrent or persistent disease. A median dose of 70 Gy (range 60-70.6) was delivered to involved nodes.
Response evaluation was performed at a median of 5 weeks after completion of radiotherapy.
Results: Neck failure was observed in 11 patients and the 3-year regional control (RC) rate was 77.1%. Neck
dissection was performed in 10 of the 11 patients; seven of these cases were successfully salvaged, and the
ultimate rate of neck control was 92%. The remaining two patients who received neck dissection had negative
pathologic results. On univariate analysis, initial nodal size > 2 cm, a less-than-complete response at the primary
site, post-radiotherapy nodal size > 1.5 cm, and post-radiotherapy nodal necrosis were associated with RC. On
multivariate analysis, less-than-complete primary site response and post-radiotherapy nodal necrosis were identified
as independent prognostic factors for RC.
Conclusions: The neck failure rate after definitive radiochemotherapy without planned neck dissection was 22%.
Two-thirds of these were successfully salvaged with neck dissection and the ultimate neck control rate was 92%.
Our results suggest that planned neck dissection might not be necessary in patients with complete response of
primary site, no evidence of residual lesion > 1.5 cm, or no necrotic lymph nodes at the 1-2 months follow-up
evaluation after radiotherapy.
Background
Radiotherapy combined with systemic therapy results in
increased locoregional control with organ preservation
in locally advanced head and neck cancers [1-4]. How-
ever, there has been controversy over neck treatment
after definitive radiochemotherapy; specifically, whether
to perform a subsequent “planned” neck dissection
(regardless of nodal response) or only “salvage” neck
dissection for persistent or recurrent disease [5]. The
rationale for routine planned neck dissection is that
pathological positivity rates are high (30%-40%) in post-
radiochemotherapy neck dissections [6,7] and the major-
ity of patients who experience a neck recurrence are
unlikely to be successfully salvaged [8]. The rationale for
observation and salvage neck dissection is the concern
of overtreatment because additional surgery for all
patients is unlikely to increase regional control rate [5].
There are some studies reporting the results of omit-
ting planned neck dissection in patients who obtain
complete response (defined ambiguously as “not clini-
cally detectable”). Their regional failure rate was gener-
ally below 10%, similar to regional control rates in
planned neck dissection series [5]. The problem here is
defining the criteria for “detectable disease”.
At Seoul National University Bundang Hospital, the
standard treatment policy is “salvage” neck dissection
for persistent or recurrent disease. Because there were
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included all patients treated with definitive radioche-
motherapy regardless of nodal response. This study
describes our experience treating patients with node-
positive head and neck cancer with definitive radioche-
motherapy without planned neck dissection. We investi-
gated the patterns of failure, neck control rate, and
prognostic factors for regional control to evaluate the
clinical outcome of our treatment policy.
Methods
We retrospectively reviewed the medical records of 50
patients with node positive head and neck cancer who
received definitive radiochemotherapy without immedi-
ate planned neck dissection between June 2003 and
August 2010 at Seoul National University Bundang
Hospital.
Patients and tumor characteristics are listed in Table
1. The study population was mostly male (82%), with a
median age of 57 years. Clinical tumor and nodal sta-
ging (according to the 7th edition of American Joint
Committee on Cancer staging system) was evaluated by
physical and endoscopic examination, computed tomo-
graphy (CT) and/or magnetic resonance imaging (MRI)
and
18F-fludeoxyglucose (FDG) positron emission tomo-
graphy (PET). Fine needle aspiration (FNA) for suspi-
cious lymph nodes was performed in 23 patients.
Lymph node with short diameter ≥1 cm (long diameter
≥0.8 cm in case of retropharyngeal node) was consid-
ered pathologic node but it was not a strict criteria.
Lymph node with necrosis, abnormal FDG uptake, or
positive for malignancy by FNA was considered patholo-
gic node regardless of its size. For PET interpretation,
there was no strict cut off maximum standardized values
(mSUV). An experienced nuclear medicine physician
interpreted the PET/CT images by visual inspection.
Foci of increased FDG uptake were evaluated by com-
parison with background and blood pool activity.
Twenty-nine patients received conventional (n = 4) or
3-dimensional conformal (n = 25) radiotherapy (3D-
C R T )w i t ham e d i a nd o s eo f7 0G y( r a n g e6 0 - 7 0 . 6G y )
to the primary tumor and involved nodes and 50 Gy to
the elective nodal area. Twenty-one patients received
intensity-modulated radiotherapy (IMRT) with a simul-
taneous integrated boost (SIB) technique. The dose pre-
scription of IMRT was as follows: 67.5 Gy at 2.25 Gy/
fraction to gross tumor (primary tumor and involved
nodes), 54 Gy at 1.8 Gy/fraction to subclinical disease,
and 49.5 Gy at 1.65 Gy/fraction to elective neck. The
chemotherapy administration sequences varied: neoadju-
vant/concurrent in 19 patients, concurrent/adjuvant in
13 patients, concurrent only in 12 patients, neoadjuvant/
concurrent/adjuvant in four patients, and neoadjuvant
only in two patients. Various cisplatin-based regimens
were administered. For neoadjuvant chemotherapy, 1-3
cycles of 5-flurouracil 1,000-1,200 mg/m
2 on day 1-4
plus cisplatin 60-80 mg/m
2 on day 1 (FP, n = 8), 1-4
cycles of docetaxel 75 mg/m
2 plus cisplatin 75 mg/m
2
on day 1 (DP, n = 7), 1-3 cycles of docetaxel 75 mg/m
2
o nd a y1 ,5 - F U1 , 0 0 0m g / m
2 on day 1-3, plus cisplatin
75 mg/m
2 on day 2-3 (DFP, n = 5), or 3 cycles of DP
plus cetuximab (400 mg/m
2 on day 1 as first dose and
then 250 mg/m
2 weekly) (n = 5) were used. For concur-
rent chemotherapy, 2-3 cycles of 3-weekly cisplatin 100
mg/m
2 on day 1 (n = 19), weekly cisplatin 30 mg/m
2 (n
= 17), weekly cetuximab 250 mg/m
2 (400 mg/m
2 as first
dose) (n = 6), weekly cisplatin 30 mg/m
2 plus cetuximab
250 mg/m
2 (n = 4), or 2 cycles of FP (n = 2) were used.
Table 1 Patient and tumor characteristics
Variable No. %
Age (years) Median 57 (range 38-
74)
Gender
Male 41 82
Female 9 18
Primary site
Nasopharynx 25 50
Oropharynx 12 24
Hypopharynx 9 18
Larynx 4 8
T classification
11 4 2 8
21 9 3 8
38 1 6
49 1 8
N classification
11 2 2 4
23 0 6 0
38 1 6
Stage
27 1 4
31 4 2 8
42 9 5 8
Histology
Squamous cell carcinoma 25 50
Nonkeratinizing undifferentiated
carcinoma
22 44
Nonkeratinizing differentiated
carcinoma
12
Keratinizing squamous cell carcinoma 2 4
Differentiation
Well differentiated 3 6
Moderate differentiated 8 16
Poorly differentiated 6 12
Undifferentiated 22 44
Not available 11 22
Initial maximal lymph node size (cm) Median 2 (range 1-7)
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17 patients until March 2008. Immediate planned neck
dissection was not performed after radiochemotherapy.
Twelve patients who had suspicious persistent or recur-
rent disease during follow-up underwent subsequent
neck dissection.
First response evaluation was performed by physical
and endoscopic examination, CT, or MRI at a median
of 5 weeks after completion of radiotherapy (range 1-14,
interquartile range 4-7). PET was performed at the first
f o l l o w - u pi n3 1p a t i e n t s .F o l l o w - u pp h y s i c a la n de n d o -
scopic examinations were performed every 1-2 months
for the first year, every 3 months for years 2-3, every 6
months for years 4-5, and every 6-12 months thereafter.
Imaging studies were performed every 3-4 months for
the first 2 years and then every 6-12 months. The pri-
mary tumor responses were evaluated according to the
Response Evaluation Criteria in Solid Tumors criteria
(RECIST) [9]. Because there were no definite criteria of
complete nodal response among studies regarding
observation and salvage neck dissection, we included all
patients treated with definitive radiochemotherapy
regardless of nodal response. If involved nodes were all
disappeared or reduced to < 0.5 cm (difficult to measure
the correct size), we observed the patient with confi-
dence. If there was an increase of ≥20% diameter in any
node or appearance of new lesion, we considered it pro-
gression and performed salvage neck dissection. How-
ever, in most other cases, we deferred the decision and
observed closely in next 1-3 months. If the lymph node
size further decreased or was stable with short diameter
< 1 cm without necrosis or abnormal FDG uptake at
second examination, the patient was observed by above
protocol. One patient who achieved partial response in
primary tumor and lymph node underwent early neck
dissection (at 10 weeks postoperatively). The patient’s
lymph node was 6.5 cm initially, and 3.8 cm at post-
radiotherapy 4 weeks. At 10 weeks post-radiotherapy,
residual node was still 3.8 cm and salvage neck dissec-
tion was performed for persistent disease. During fol-
low-up, increase of ≥20% diameter compared with prior
smallest size in any single node or appearance of new
lesion was considered recurrent nodal disease and sal-
vage treatment was performed.
Overall survival (OS), recurrence-free survival (RFS),
local control (LC), regional control (RC), and distant
control (DC) rates were calculated using the Kaplan-
Meier method. Data for patients who were alive or dead
w i t h o u te a c ht y p eo fr e c u r r e n c ew e r eu s e da sc e n s o r e d
data in calculating LC/RC/DC rates. Prognostic factors
such as age, gender, primary site, T/N classification,
initial lymph node size, radiotherapy modality, che-
motherapy administration sequence, primary tumor
response, post-radiotherapy lymph node size/necrosis,
and PET reading of positive residual nodal disease were
evaluated using log-rank statistics. Among the factors,
those with p < 0.2 were selected and included in the
multivariate regression analysis using the Cox propor-
tional hazards regression model. The statistical analysis
was performed with PASW version 17.0 (SPSS Inc., Chi-
cago, IL).
Results
The median follow-up duration after radiotherapy was
36.7 months (range 14.0-90.5). A total of 17 patients
experienced recurrences and two patients died. The pat-
terns of first failure and overall failure at the time of the
last follow-up are shown in Figure 1. Of the five patients
who experienced regional recurrence as an isolated first
recurrence, two experienced subsequent distant metasta-
sis and two experienced subsequent local and distant
failure. Of the four patients who experienced local
recurrence as an isolated first recurrence, one patient
experienced subsequent regional failure and one experi-
enced subsequent regional and distant failure. Overall
local, regional, and distant failure developed in 10, 11,
and 10 patients, respectively. The 3-year OS, RFS, LC,
RC, and DC rates were 95.7%, 62.7%, 77.2%, 77.1%, and
78.2%, respectively.
Regional recurrence developed in 11 patients (crude
rate 22%) at a median of 4.9 months after radiotherapy
(range 2.3-23.6, interquartile range 2.6-7.0). Ipsilateral
level II was the most common site of regional failure.
Neck dissection for suspicious persistent or recurrent
disease was performed in 12 patients at 2.3-24.5 months
(median 6 months) after radiotherapy. Of these, two
patients had no metastatic lymph nodes and 10 had
metastatic lymph nodes in the neck. Of these 10
patients, seven were successfully salvaged, and the ulti-
mate neck control rate was 92%. With the exception of
two patients who developed distant metastasis, the other
five of these seven patients were alive without disease at
the last follow-up. Two patients with isolated local fail-
ure and one patient with isolated lung metastasis were
also successfully salvaged with surgery and chemother-
apy. Thus, 8 of 17 patients with recurrence were alive
without disease at the last follow-up (median 24.6
months, range 9.7-88.1 months after recurrence).
We evaluated candidate parameters such as age, gen-
der, primary site, T/N classification, initial lymph node
size, radiotherapy modality, chemotherapy administra-
tion sequence, primary tumor response, post-radiother-
apy lymph node size/necrosis, and PET reading of
positive residual nodal disease to identify prognostic fac-
tors for regional control, and the results are listed in
Table 2. On univariate analysis, initial nodal size > 2 cm
(3-year RC 88.0% vs. 63.6%, p = 0.022), post-radiother-
apy primary tumor response less than complete
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nodal size > 1.5 cm (83.5% vs. 20.0%, p < 0.001), and
post-radiotherapy nodal necrosis (87.8% vs. 33.3%, p =
0.002) were associated with poor regional control.
Administration of chemotherapy was heterogeneous and
we divided patients into 3 groups; neoadjuvant plus con-
current, concurrent plus adjuvant, and concurrent only;
corresponding 3-year RC rates were 71.4%, 94.1%, and
64.3%, respectively (p = 0.123). On multivariate analysis,
a less-than-complete primary site response (hazard ratio
8.926, 95% confidence interval 2.38-33.47, p = 0.001)
Figure 1 Patterns of (A) first failure and (B) overall failure.O f
the five patients who experienced regional recurrence as an
isolated first recurrence, two experienced subsequent distant
metastasis and two experienced subsequent local and distant
failure. Of the four patients who experienced local recurrence as an
isolated first recurrence, one patient experienced subsequent
regional failure and one experienced subsequent regional and
distant failure.
Table 2 Univariate analysis to identify prognostic factors
for regional control
Variable No. 3- year RC p value
Age (years) 0.146
≤ 60 32 84.4
> 60 18 61.9
Gender 0.093
Male 41 72.0
Female 9 100.0
Primary site 0.22
Nasopharynx 25 83.6
Non-Nasopharynx 25 72.0
T classification 0.121
1 14 68.8
2 19 84.2
3 8 100
4 9 55.6
T classification 0.05
1-3 41 82.0
4 9 55.6
N classification 0.43
1 12 91.7
2 30 71.9
3 8 75.0
N classification 0.194
1 12 91.7
2-3 38 72.7
Initial maximal lymph node size (cm) 0.022
≤ 2 28 88.0
> 2 22 63.6
RT modality 0.887
Conventional 4 75
3D-CRT 25 73.8
IMRT 21 81.0
Chemotherapy sequence 0.123
Neoadjuvant + concurrent
1 21 71.4
Concurrent + adjuvant
2 17 94.1
Concurrent only 12 64.3
Primary tumor response < 0.001
Complete response 38 88.1
Partial response 10 50.0
Progressive disease 2 0.0
Primary tumor response < 0.001
Complete response 38 88.1
Non-complete response 12 41.7
Residual maximal lymph node size (cm) < 0.001
≤ 1.5 45 83.5
> 1.5 5 20.0
Lymph node necrosis < 0.001
No 41 87.8
Yes 9 33.3
Follow-up PET report 0.349
Residual disease 4 50
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7.413, 95% confidence interval 2.03-27.14, p = 0.002)
were identified as independent prognostic factors for
regional control.
PET as a first evaluation was performed in 31 patients.
Only four of the 31 patients showed positive PET results
with mSUV of 1.3, 2.8, 3.3, and 5.0, respectively. Two of
them (mSUV 3.3 & 5.0) experienced regional failure.
One patient had 1.7 cm necrotic lymph node with
abnormal FDG uptake (mSUV 3.3) at 3 weeks post-
radiotherapy. We decided that post-radiotherapy 3
weeks was too early to determine overall response and
re-checked CT 8 weeks later. At 11 weeks, lymph node
further decreased but was progressed in next follow-up
CT. Another patient with regional recurrence had 1-cm
lymph nodes without necrosis at 8 weeks after radio-
therapy, and PET showed small but hypermetabolic
lymph nodes (mSUV 4.2 and 5.0) at that time. Because
there were small lymph nodes without necrosis, and
FDG uptake decreased compared with pre-treatment
value (mSUV 9.0), we observed without immediate neck
dissection. However after 3 months, lymph nodes
increased with necrosis and FDG uptake also increased
up to mSUV 12.5, and the patients underwent salvage
neck dissection. Since PET was performed in only a sub-
set of the patients (n = 31) at the first follow-up, we
analyzed subset analysis in patients who checked PET.
Positive and negative PET results were reported in 4
and 27 patients, respectively, and the corresponding 3-
year RC rates were 50% and 78.1% (p = 0.115). When
we included patients who did not perform PET and
divided patients into 3 groups (residual disease, normal/
reactive change, and no PET), and 3-year RC rates were
not significantly different (p = 0.349). We could not find
a n yp r o g n o s t i cs i g n i f i c a n c ef o rr e g i o n a lc o n t r o lb yt h e
statistical analysis using several arbitrary cut off points
of mSUVs regardless of the interpretation by the specia-
lists in Nuclear Medicine.
Discussion
We report the clinical outcomes of node-positive head
and neck cancer patients who were treated with defini-
tive radiochemotherapy without planned neck dissec-
tion. There are some studies reporting the results of
omitting planned neck dissection in patients who obtain
complete response. Their regional failure rate was gen-
erally below 10%, similar to regional control rates in
planned neck dissection series [5]. Because there were
no definite criteria of complete nodal response, we
included all patients treated with definitive radioche-
motherapy regardless of nodal response. Overall, 11
patients (22%) experienced neck failure. However, seven
of these were successfully salvaged with neck dissection,
and the ultimate neck control rate was 92%. Moreover,
we tried to treat all recurrences aggressively, and eight
of 17 patients with recurrence were alive without disease
at the last follow-up. Therefore, aggressive salvage treat-
ment should be considered if the general condition of
the patient allows it.
Several studies support the policy of omitting planned
neck dissections in patients who obtain a complete
response to radio(chemo)therapy [10-14]. However,
these studies used various definitions of “complete
response” of the neck. Some studies evaluated response
by physical examination, and a complete response was
defined ambiguously as “not clinically detectable”
[10,15]. Many studies defined complete response as
complete disappearance of any detectable disease. The
problem here is defining the criteria for “detectable dis-
ease”. According to the definition of response evaluation
criteria in solid tumors (RECIST), complete response of
a lymph node is the reduction of the short axis to < 10
mm [9]. However, some studies evaluating neck
response after definitive radiochemotherapy used criteria
of < 1 cm or ≤1 . 5c mf o rm a x i m u md i a m e t e rw i t h o u t
any focal abnormality [11,13]. Because of these different
criteria, we included all patients treated with definitive
radiochemotherapy regardless of nodal response and
analyzed factors related to regional recurrence.
As a result, initial and post-radiotherapy nodal size,
post-radiotherapy nodal necrosis, and post-radiotherapy
primary tumor response were associated with regional
control. Post-radiotherapy nodal size of ≤1.5 cm and no
necrosis have been reported as predictors of negative
neck dissection pathology in a previous study [13]. In
our study, there was only one regional recurrence
among patients with complete response of the primary
site, no evidence of residual lesion > 1.5 cm or necrotic
lymph nodes at the first follow-up evaluation. The
patient had 1-cm lymph nodes without necrosis at 8
weeks after radiotherapy, and PET showed small but
hypermetabolic lymph nodes (mSUV 4.2 and 5.0) at that
time. Because there were small lymph nodes without
necrosis, and FDG uptake decreased compared with
pre-treatment value (mSUV 9.0), we observed without
immediate neck dissection. However, lymph nodes
increased with necrosis and FDG uptake also increased
up to mSUV 12.5 after 3 months and the patients
underwent salvage neck dissection.
Table 2 Univariate analysis to identify prognostic factors
for regional control (Continued)
Normal/Reactive change 27 78.1
Not available 19 78.9
RC: regional control
1. Two patients who received neoadjuvant chemotherapy only were included
2. Four patients who received additional one cycle of neoadjuvant
chemotherapy were included
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residual neck disease and reported high negative predic-
tive values [16,17]. In our study, PET was performed in
only a subset of the patients (n = 31) at the first follow-
up. Positive and negative PET results were reported in 4
and 27 patients, respectively, and the corresponding 3-
year RC rates were 50% and 78.1% (p = 0.115). Since
the sample size was too small to determine definite con-
clusion, the role of PET should be further investigated
in the future.
Limitations of this study include the relatively short
follow-up period, small number of patients, heteroge-
neous patient population and treatment regimen, and
retrospective nature. Nasopharyngeal carcinoma is
highly radiosensitive and mainstay of treatment is radio-
therapy with chemotherapy. Despite their radiosensitiv-
ity, the incidence of persistent or recurrent neck disease
has been reported to be 5-18% [18,19]. However, neck
control (observation or immediate neck dissection)
should be the major concern whenever response of
lymph node is less than complete response after radio-
chemotherapy whether primary is nasopharyngeal or
non-nasopharyngeal lesion. Taking into account the dif-
ferent sensitivity to radiochemotherapy between naso-
pharyngeal and non-nasopharyngeal cancer, we analyzed
primary site as one of the candidate prognostic factor.
The 3-year RC rate of nasopharyngeal carcinoma and
non-nasopharyngeal carcinoma was 83.6% and 72.0%
respectively and difference was statistically not signifi-
cant (p = 0.22). A large diversity of treatment regimens
is another limitation. Chemotherapy sequence and
radiotherapy modality did not show significant prognos-
tic impact on regional recurrence.
Conclusions
In conclusion, the neck failure rate after definitive radio-
chemotherapy without planned neck dissection was 22%.
However, two-thirds of these were successfully salvaged
by neck dissection and the ultimate neck control rate
was 92%. Based on analysis of prognostic factors,
patients with complete response at the primary site, no
evidence of residual lesion > 1.5 cm, or no necrotic
lymph nodes at the 1-2 month follow-up evaluation
after radiotherapy might be spared from planned neck
dissection. However, prospective evaluation in a larger
group of patients would be clearly necessary before this
recommendation can be included in routine manage-
ment of patients.
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